🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

More data from #HeliosB on NTproBNP and troponin presented #HFSA2024 - vutrisiran vs placebo on the background of tafamidis in 40% at baseline and another 10% drop in during the trial. Consistent effect across all subgroups, including those on baseline tafamidis #CardioTwitter

Read about the opportunities to apply #AI to improve CV trials throughout their life cycle, from enrollment to dissemination, in this #JACC state-of-the-art review: bit.ly/3Cg3XMQ #ArtificialIntelligence Jon Cunningham Geoff Tison Ankeet S. Bhatt, MD, MBA Trejeeve (Tre) Martyn Sneha Shah Jain, MD, MBA

How can we streamline, automate, and improve, CV clinical trials with #AI? Our HF Collaboratory review in JACC Journals outlines opportunities in enrollment, adjudication, and dissemination, & role of the FDA. Let's move from potential to reality! Harlan Krumholz @JJheart_doc

The role of AI in Clinical Trial Conduct. We review how can medically trained LLMs can help improve clinical trial scoping and recruitment. bit.ly/3Cg3XMQ led by Jon Cunningham with Ankeet S. Bhatt, MD, MBA Geoff Tison Mona Fiuzat Mitchell Psotka Harlan Krumholz Christopher O'Connor HF Collaboratory

Congratulations to the #SUMMIT team for their practice-changing trial showing reduced time-to-first-event for CV death or worsening #HF with #tirzepatide in obesity-HFpEF. A huge win for this patient population. Now lets define mechanisms and understand who benefits most!

Another day, another #ATTR amyloidosis trial published in NEJM! Exciting late-breaker American Heart Association #AHA24, looking at 1+ year data with #CRISPR gene editing by Intellia Therapeutics. The bottom line is all good news – sustained #TTR reduction, positive clinical signals, promising

Can AI automate HF adjudication in global clinical trials? Our latest #AHA2024 SimPub Circ: Heart Failure In the DELIVER trial, our AI model for HF hosp was -Accurate -Generated identical treatment estimate for dapa as human CEC -Extracts evidence of HF Paper: twtr.to/7qxb_

Congrats Harsh on #AHA presentation & simpub in JACC Journals we describe early HF outcomes/GDMT in a sick older cohort admitted to a virtual hospital at home model bit.ly/48TkiDw Cleveland Clinic Heart, Vascular & Thoracic Jerry Estep BiykemBozkurt Jessica Hohman Richard Rothman CCF Cardiology Fellows #HaH #GDMT

⭐️ ⭐️ We are so proud to welcome the CVM class of 2028 to the CCF Cardiology Fellows family! We cannot wait for you to join us in Cleveland next summer! venu menon Ran Lee, MD, FACC Andrew Higgins Andrew Abboud Evan Whitehead Lars Svensson Samir Kapadia Cleveland Clinic Heart, Vascular & Thoracic #CCFCardsFam

Excited to share our work on the use of #GDMT in patients with HeartMate3 #LVAD! 🫀 Special thanks to Dr. Trejeeve (Tre) Martyn for the mentorship. Phoo Cleveland Clinic Heart, Vascular & Thoracic Read more in EJHF European Society of Cardiology Journals 👇🔗 onlinelibrary.wiley.com/doi/10.1002/ej…

Vutrisiran for transthyrtin amyloid cardiomyopathy is now FDA approved to reduce mortality, CVH, and urgent HF visits Label alnylam.com/sites/default/… #CardioTwitter

A monumental day for the #ATTR #amyloidosis field: #Vutrisiran is now FDA approved for ATTR-CM! The landmark #HELIOS-B trial hit 10/10 prespecified endpoints including improved all-cause mortality. Congratulations to everyone who contributed to the development/approval, and a

And then there were 3! Ronald Witteles Ahmad Masri Martha Grogan MD Mazen Hanna Brett Sperry, MD Kevin Alexander Yevgeniy Brailovsky DO MSc FACC Melissa Lyle Rafael Fonseca MD 🦔🇺🇸🏜🇲🇽 Justin L. Grodin investors.alnylam.com/press-release?…

More #AI innovations Cleveland Clinic, as Trejeeve (Tre) Martyn discusses research he presented at #ACC25 on the use of artificial intelligence in screening for transthyretin cardiac amyloidosis clinical trials.

Trejeeve (Tre) Martyn provided an outstanding practical example of AI to facilitate delivery of cutting edge care to under-treated patients ACC Media Center #ACC25

📣Can wearable accelerometers predict HF outcomes? Original research with a subgroup of DETERMINE trial patients showed: ⬇️Physical activity assessed by accelerometer🏃🏾‍♂️ --> ⬇️KCCQ, ⬇️ 6MWD, ⬆️ NT-proBNP #Wearables #HFoutcomes 🔗bit.ly/4cAnB4f

Now in its third year, our DSMB Academy Training Workshop continues to make a lasting impact. Hear directly from participants as they share what the experience has meant to them. We’re proud to support the next generation of clinical trial leaders.

🔥 #CONFIDENCE in NEJM Simultaneous initiation of #SGLT2i + #nsMRA safely and rapidly delivers in patients with CKD & T2D A new age of combination therapies has arrived in #CKM care #ERA25 nejm.org/doi/full/10.10…

When the CEO is one of us. Cleveland Clinic Heart, Vascular & Thoracic Cleveland Clinic The Team

Thanks to the entire JCF community for supporting the growing impact of the journal - onward and upward we go. Together. Anu Lala-Trindade Shashank Sinha, MD, MSc, FACC, FAHA, FHFSA Dr. Martha Gulati ♥️🫀❤️‍🩹🇨🇦 Andrew J Sauer MD Nosheen Reza, MD, MS Jason N. Katz HFSA Michael Felker